spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  BioMarin 

 HSMN NewsFeed - 23 Nov 2022
BioMarin Announces Advancements in FDA Review of ROCTAVIAN(TM) (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jun 2022
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2022
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Nov 2021
BioMarin Receives FDA Approval for VOXZOGO(TM) (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Sep 2021
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Aug 2021
European Commission Approves BioMarin's VOXZOGO(R) (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jun 2021
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Mar 2021
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Aug 2020
BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Dec 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Aug 2019
Glycomine, Inc. Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 9 Jul 2019
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2019
Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Nov 2018
ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Nov 2018
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2018
Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jun 2018
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2018
Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 13 Nov 2017
Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2017
FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2017
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2017
BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2017
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Nov 2016
Oncolytics Biotech(R) Inc. Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 Mar 2016
ProNAi Therapeutics Appoints Jeffrey H. Cooper and Tran Nguyen to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2015
Amicus Therapeutics Strengthens Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2014
Coherus BioSciences Appoints Dr. V. Bryan Lawlis, Jr. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2014
Retrophin Names Stephen Aselage President and Chief Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 May 2014
Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2014
Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2014
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Jan 2014
BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2013
Vital Therapies, Inc. Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2013
KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2012
Biopharmaceutical Executive Dr. Alan Lewis Appointed as CEO of Medistem
Regenerative Medicine Personnel
 HSMN NewsFeed - 5 Sep 2012
BioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2012
Jeff Cooper Joins KaloBios as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2011
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
BioMarin Acquires ZyStor Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2010
BioMarin to Acquire LEAD Therapeutics
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 11 Jan 2010
Teleflex Incorporated Names Richard (Randy) Meier Chief Financial Officer
Devices Personnel
 HSMN NewsFeed - 30 Nov 2009
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jun 2009
Richard A. Meier Appointed to STAAR Surgical Board of Directors
Devices Ophthalmology Personnel
 HSMN NewsFeed - 9 Jun 2009
William Aliski Named FoldRx Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Apr 2009
Merck Serono Launches Kuvan(R) in Europe
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2009
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2008
Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Sep 2008
Merck Serono's Kuvan(R) Recommended for European Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2008
Pipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2008
Naglazyme Approved by Japanese Ministry of Health
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jan 2008
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2007
BioMarin Announces FDA Approval for Kuvan
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2007
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Sep 2007
Enobia Pharma Raises $40.1 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Aug 2007
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
Kuvan Receives Priority Review Status from FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
BioMarin Initiates Expanded Access Program for Kuvan in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2007
NeurogesX Appoints BioMarin CEO Bienaime as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Mar 2007
Rincon Pharmaceuticals Appoints Dr. Peter B. Heifetz as Chief Scientific Officer, Drs. Jacqueline J. Johnson and Alan J. Lewis to Board of Directors, and Drs. Katherine S. Bowdish and Mich B. Hein to Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2007
TechniScan Medical Systems Taps Dr. John Klock for Board of Directors
Devices Radiology Personnel
 HSMN NewsFeed - 20 Feb 2007
Bio-Rad Announces the Appointment of New Board Member
Diagnostics Personnel
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 28 Aug 2006
BioMarin Announces U.S. Launch of Orapred ODT Through Alliant Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2006
BioMarin and Alliant Announce FDA Approval of Orapred ODT
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 28 Apr 2006
FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Mar 2006
BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Mar 2006
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2006
BioMarin Receives Marketing Approval for Naglazyme in European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jan 2006
BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2006
Nektar Therapeutics Appoints New Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2006
BioMarin Establishes Commercial Operations in Europe
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
BioMarin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.